Announcements Trials
Browse Landscape

Phase

Phase 2/3 1

Status

Withdrawn 1Unknown 1

Sponsor Class

OTHER_GOV 1OTHER 1

Study Type

Observational 1Interventional 1

Sponsor

Cancer Type

Head & Neck 2

Conditions

Thyroid Neoplasms 2Neuroendocrine Tumors 2Primary Breast Cancer 1Parkinson Disease 1Malignancy of Thyroid Nodules 1Adenocarcinoma, Follicular 1

Interventions

Iodine-131 21lenvatinib 17Magnetic Resonance Spectroscopy 17trametinib 13Sorafenib 13Thyrotropin Alfa 12pembrolizumab 11dabrafenib 11Thyroidectomy 10Surgical Procedures, Operative 10Thyroxine 9Paclitaxel 9vandetanib 8selpercatinib 8Sunitinib 7Nivolumab 7Fluorodeoxyglucose F18 7cabozantinib 6anlotinib 6Everolimus 6Biopsy 6pazopanib 5Vemurafenib 5Triiodothyronine 5Specimen Handling 5Saline Solution 5Radiotherapy 5Radiofrequency Ablation 5Iodine-124 5Cyclophosphamide 5

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Thyroid Neoplasms × Iodine-123 × Clear all
NCT00373711 2022-06-21

Comparison of I-124 PET/CT, F-18 FDG PET/CT & I-123 Whole Body Scintigraphy for Recurrent Thyroid CA

Stanford University

Withdrawn
Head & Neck

Thyroid Neoplasms

NCT02418247 2017-01-20

Minimize Radioactive Iodine Ablation Of Remnant Thyroid in Differentiated Thyroid Cancer

National Cancer Center, Korea

Phase 2/3 Unknown
556 enrolled
Head & Neck

Thyroid Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡